Inotrem

Developer of peptide immunotherapies for treating septic shock and acute myocardial infarction

placeParis, Ile De France, France calendar_todayFounded 2013 groups35 employees language inotrem.com

Innovation

7 patent families (2 granted) — focus: Physics & computing, Chemistry & metallurgy, Human necessities; filing pace slowing. Cited 418 times.

YearFilings
20151
20161
20181
20202
20215
20222
20235
20244
20252
20261

Investor mix

13 investors on record; lead investors include Edmond de Rothschild, Sofinnova Partners, Fountain Healthcare Partners, Morningside.

Investor typeCountShare
Venture capital538%
Private equity215%
Bank & private debt323%
Other / undisclosed323%
Coming soon